Literature DB >> 3195998

High hepatic excretion in humans of cefpiramide, a new cephalosporin.

J M Brogard1, F Jehl, M Adloff, J F Blickle, H Monteil.   

Abstract

After intravenous administration of 1 g of cefpiramide, the biliary elimination of the drug was studied by using high-performance liquid chromatography. In five healthy volunteers, a mean peak concentration of 339 +/- 107 (standard error of the mean) micrograms/ml was measured in aspirated duodenal fluid during h 2 after administration, and 1.2% of the dose given was recovered over a 4-h period. A maximal concentration of 1,161 +/- 392 micrograms/ml was reached during h 2 in T-tube bile from 10 recently cholecystectomized patients, with a 24-h biliary recovery of 23.1%; urinary recovery over the same period averaged 49.4%. In 10 patients undergoing cholecystectomy, the concentrations in serum, choledochal bile, gallbladder bile, and gallbladder wall 1 h after cefpiramide administration were 157 +/- 21, 1,726 +/- 501, and 84 +/- 33 micrograms/ml and 23 +/- 4 micrograms/g, respectively. These figures represent the highest biliary concentrations attained so far with a beta-lactam antibiotic and are therefore a good prerequisite for treatment of biliary tract infections with cefpiramide.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3195998      PMCID: PMC175868          DOI: 10.1128/AAC.32.9.1360

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  10 in total

1.  Bile drainage after choledochostomy in man, with some observations on biliary fistula.

Authors:  F F RUNDLE; M H CASS; B ROBSON; M MIDDLETON
Journal:  Surgery       Date:  1955-06       Impact factor: 3.982

2.  Hepatic clearance theory and clinical application.

Authors:  V HOENIG; O SCHUCK
Journal:  Rev Czech Med       Date:  1956

3.  Hospital routine analysis of penicillins, third-generation cephalosporins and aztreonam by conventional and high-speed high-performance liquid chromatography.

Authors:  F Jehl; P Birckel; H Monteil
Journal:  J Chromatogr       Date:  1987-01-23

4.  Biliary elimination of ceftazidime.

Authors:  J M Brogard; F Jehl; D Pâris-Bockel; J F Blicklé; M Adloff; H Monteil
Journal:  J Antimicrob Chemother       Date:  1987-05       Impact factor: 5.790

5.  In vitro antibacterial activity of cefpiramide.

Authors:  M A Pfaller; A C Niles; P R Murray
Journal:  Antimicrob Agents Chemother       Date:  1984-03       Impact factor: 5.191

6.  Biliary excretion and pharmacokinetics of cefoperazone in humans.

Authors:  B Kemmerich; H Lode; K Borner; D Belmega; T Jendroschek; P Koeppe; G Goertz
Journal:  J Antimicrob Chemother       Date:  1983-07       Impact factor: 5.790

7.  Pharmacokinetics of cefpiramide (SM-1652) in humans.

Authors:  K Nakagawa; M Koyama; H Matsui; C Ikeda; K Yano; N Nakatsuru; K Yoshinaga; T Noguchi
Journal:  Antimicrob Agents Chemother       Date:  1984-02       Impact factor: 5.191

8.  Antimicrobial activities of BMY-28142, cefbuperazone, and cefpiramide compared with those of other cephalosporins.

Authors:  N J Khan; J A Bihl; R F Schell; J L LeFrock; S J Weber
Journal:  Antimicrob Agents Chemother       Date:  1984-10       Impact factor: 5.191

9.  Cefpiramide: comparative in-vitro activity and beta-lactamase stability.

Authors:  A L Barry; R N Jones; C Thornsberry; P C Fuchs; L W Ayers; T L Gavan; E H Gerlach; H M Sommers
Journal:  J Antimicrob Chemother       Date:  1985-09       Impact factor: 5.790

10.  Comparative in vitro activities of cefpiramide and apalcillin individually and in combination.

Authors:  J D Allan; G M Eliopoulos; M J Ferraro; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1985-05       Impact factor: 5.191

  10 in total
  2 in total

1.  Cefpiramide kinetics and plasma protein binding in cholestasis.

Authors:  F Demontes-Mainard; G Vinçon; L Labat; M Amouretti; J Necciari; G Kieffer; B Bannwarth
Journal:  Br J Clin Pharmacol       Date:  1994-03       Impact factor: 4.335

2.  Biliary excretion of cefixime: assessment in patients provided with T-tube drainage.

Authors:  J F Westphal; F Jehl; M Schloegel; H Monteil; J M Brogard
Journal:  Antimicrob Agents Chemother       Date:  1993-07       Impact factor: 5.191

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.